Edition:
India

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

99.00EUR
18 Sep 2020
Change (% chg)

€1.00 (+1.02%)
Prev Close
€98.00
Open
€98.22
Day's High
€99.74
Day's Low
€98.22
Volume
381,419
Avg. Vol
416,479
52-wk High
€114.45
52-wk Low
€60.18

Latest Key Developments (Source: Significant Developments)

UCB Enters Into Collaboration With Roche To Develop Treatment For Alzheimer's Disease
Wednesday, 29 Jul 2020 

July 29 (Reuters) - UCB SA ::UCB ENTERS INTO COLLABORATION WITH ROCHE TO DEVELOP ANTIBODY TREATMENT FOR PEOPLE LIVING WITH ALZHEIMER'S DISEASE.UCB TO PROVIDE TO ROCHE AND GENENTECH EXCLUSIVE, WORLD-WIDE LICENSE TO UCB'S UCB0107, AN INNOVATIVE ANTI-TAU ANTIBODY TREATMENT.UCB WILL RECEIVE AN INITIAL UPFRONT PAYMENT AND, AFTER POSITIVE COMPLETION OF PROOF-OF-CONCEPT IN ALZHEIMER'S DISEASE, IS ELIGIBLE TO RECEIVE FURTHER POTENTIAL PAYMENTS WITH A TOTAL POTENTIAL CONSIDERATION APPROACHING US $2 BILLION.UCB TO FUND AND PERFORM INITIAL PROOF-OF-CONCEPT STUDY IN ALZHEIMER'S DISEASE.  Full Article

UCB And Ferring Pharmaceuticals Announce Co-Promotion Of Cimzia®
Tuesday, 7 Jul 2020 

July 7 (Reuters) - Ucb SA ::UCB AND FERRING PHARMACEUTICALS ANNOUNCE CO-PROMOTION OF CIMZIA® (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE CROHN'S DISEASE.FERRING JOINS WITH UCB TO PROMOTE CIMZIA PREFILLED SYRINGE FOR CROHN'S DISEASE IN U.S..  Full Article

UCB Acquires Ra Pharmaceuticals And Updates 2020 Financial Guidance
Thursday, 2 Apr 2020 

April 2 (Reuters) - UCB SA ::COMPLETES ACQUISITION OF RA PHARMACEUTICALS – TO DELIVER DIFFERENTIATED THERAPIES TO PATIENTS.THE CLOSING OF THIS ACQUISITION LEADS TO AN UPDATE OF UCB’S 2020 FINANCIAL GUIDANCE – AS ANNOUNCED WITH THE FY 2019 RESULTS PRESS RELEASE ON 20 FEBRUARY 2020.THE UPDATED FINANCIAL GUIDANCE ABOVE DOES NOT REFLECT ANY POTENTIAL IMPACTS FROM THE EVOLVING COVID-19 PANDEMIC.FOR 2020, UCB IS AIMING FOR REVENUES IN THE RANGE OF € 5.05 – 5.15 BILLION THANKS TO THE CURRENT CORE PRODUCT GROWTH AND NEW PATIENT POPULATIONS BEING SERVED.INCLUSION OF RA PHARMA WILL BE DILUTIVE TO UCB’S MID-TERM EARNINGS LEVEL DUE TO R&D INVESTMENTS.CORE EARNINGS PER SHARE ARE NOW EXPECTED IN THE RANGE OF € 4.40 – 4.80 BASED ON AN AVERAGE OF 187 MILLION SHARES OUTSTANDING.AS RESULT, MID-TERM TARGET OF UCB REACHING A REBITDA RATIO (TO REVENUE) OF 31% MOVES TO 2022 FROM 2021 AS PREVIOUSLY GUIDED.ACQUISITION IS EXPECTED TO BE CORE EPS ACCRETIVE FROM 2024 ONWARDS AND TO ENABLE ACCELERATED TOP AND BOTTOM LINE GROWTH FOR UCB FROM 2024 ONWARDS.UNDERLYING PROFITABILITY, REBITDA, IN RANGE OF 26-27% OF REVENUE, WILL REFLECT HIGH R&D INVESTMENT LEVEL, INCLUDING INVESTMENT FOR RA PHARMA PIPELINE.  Full Article

Proximus Announces Resignation Of CFO Sandrine Dufour
Monday, 9 Mar 2020 

March 9 (Reuters) - PROXIMUS NV ::PROXIMUS ANNOUNCES THAT CFO SANDRINE DUFOUR HAS DECIDED TO LEAVE COMPANY ON 1 JUNE.DUFOUR HAS ACCEPTED POSITION OF CFO AT UCB.  Full Article

UCB Announces Appointment Of Sandrine Dufour As New CFO
Monday, 9 Mar 2020 

March 9 (Reuters) - UCB SA ::UCB ANNOUNCES APPOINTMENT OF SANDRINE DUFOUR AS NEW CHIEF FINANCIAL OFFICER.DETLEF THIELGEN WILL BE LEAVING UCB DURING FIRST SEMESTER OF 2020.JEAN-CHRISTOPHE TELLIER WILL ENSURE INTERIM ROLE OF CFO UNTIL MRS. DUFOUR JOINS ON JULY 1ST.MRS. DUFOUR WILL BEGIN HER EMPLOYMENT ON 1 JULY 2020.  Full Article

Advanz Pharma Announces Definitive Agreement To Acquire The Rights To A Portfolio Of Alprostadil Products From UCB For Approximately $84 Mln
Friday, 6 Mar 2020 

March 6 (Reuters) - Advanz Pharma Corp Ltd ::ADVANZ PHARMA CORP. LIMITED ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE THE RIGHTS TO A PORTFOLIO OF ALPROSTADIL PRODUCTS FROM UCB S.A. FOR APPROXIMATELY $84 MILLION.ADVANZ PHARMA CORP - ON DEAL CLOSING, CO WILL ALSO PAY A DEPOSIT FOR INVENTORY OF ABOUT $14 MILLION.ADVANZ PHARMA- COMBINED SALES OF ALPROSTADIL BRANDS GENERATED ABOUT $33.3 MILLION IN REVENUE IN 2019 IN TERRITORIES WHERE ADVANZ PHARMA WILL HOLD RIGHTS.ADVANZ PHARMA CORP - INTENDS TO PAY FOR ACQUISITION WITH CASH ON HAND.  Full Article

UCB FY Revenue Up At 4.9 Billion Euros
Thursday, 20 Feb 2020 

Feb 20 (Reuters) - Ucb SA ::SEES FY 2020 REBITDA 28 - 29% OF REVENUE.FY PROFIT AMOUNTED TO EUR 817 MILLION OF WHICH EUR 792 MILLION (-1%; +15% CER) IS ATTRIBUTABLE TO UCB SHAREHOLDERS.BRIVIACT (BRIVARACETAM), REACHED NET SALES OF € 221 MILLION.FINANCIAL OUTLOOK FOR 2020: REVENUE EXPECTED TO REACH EUR 5.05 - 5.15 BILLION.FY REVENUE REACHED EUR 4.9 BILLION (+6%, +7% CER) NET SALES INCREASED TO EUR 4.7 BILLION (+6%).WE COULD POTENTIALLY LAUNCH UP TO 7 PRODUCTS BY 2025 TO CREATE PATIENT VALUE FOR SPECIFIC POPULATIONS NOW AND INTO FUTURE.RESEARCH AND DEVELOPMENT UPDATE: BIMEKIZUMAB WITH THREE POSITIVE PHASE 3 RESULTS IN PSORIASIS AND A NEW PHASE 3 PROGRAM IN HIDRADENITIS SUPPURATIVA STARTED; CIMZIA WITH APPROVALS IN CHINA AND JAPAN.PHASE 3 PROGRAM BE HEARD STARTS IN Q1 2020.CIMZI NET SALES INCREASED TO MORE THAN € 1.7 BILLION, DRIVEN BY CONTINUED, SUSTAINABLE GROWTH IN ALL REGIONS..FY GROSS PROFIT REACHED EUR 3.65 BILLION.NEUROLOGY: UCB'S EPILEPSY FRANCHISE REACHED NET SALES OF € 2.3 BILLION, A PLUS OF 12%.2019 INCOME TAX EXPENSES WERE EUR 146 MILLION COMPARED TO EUR 200 MILLION IN 2018.VIMPAT, WITH NET SALES OF MORE THAN € 1.3 BILLION, SHOWS CONTINUED DOUBLE-DIGIT STRONG GROWTH IN ALL REGIONS THANKS TO REACHING MORE AND MORE PEOPLE LIVING WITH EPILEPSY..FY NET FINANCIAL EXPENSES INCREASED BY 15% TO EUR 107 MILLION.KEPPRA (LEVETIRACETAM) FOR EPILEPSY, REPORTED NET SALES OF € 770 MILLION,.PHASE 3 PROGRAM BE HEARD STARTS IN Q1 2020, FIRST HEADLINE RESULTS ARE EXPECTED IN H1 2023.  Full Article

UCB Raises FY Guidance, Expects Now Revenue of About EUR 4.9 Bln
Friday, 10 Jan 2020 

Jan 10 (Reuters) - Ucb SA ::UCB UPDATES ITS FINANCIAL OUTLOOK FOR 2019.UCB SA - STRONGER THAN EXPECTED NET SALES LEAD TO HIGHER EARNINGS LEVEL IN 2019.UCB SA - TOTAL REVENUE IN 2019 ARE EXPECTED TO REACH APPROX. € 4.9BN – PREVIOUS OUTLOOK WAS IN THE RANGE OF € 4.6 – 4.7BLN.UCB SA - UNDERLYING PROFITABILITY (RECURRING EBITDA) IS NOW EXPECTED AT LEAST AT UPPER END OF RANGE OF 27% - 29% OF REVENUE - PREVIOUS GUIDANCE WAS IN RANGE OF 27% - 29%.UCB SA - CORE EPS 2019 ARE NOW EXPECTED TO BE HIGHER THAN EUR 4.80 - PREVIOUS RANGE WAS EUR 4.40 - 4.80.UCB SA - CORE EPS ARE NOW EXPECTED TO BE HIGHER THAN € 4.80 FOR 2019.UCB SA - 2019 UNDERLYING PROFITABILITY (RECURRING EBITDA) IS NOW EXPECTED AT LEAST AT THE UPPER END OF THE RANGE OF 27% - 29% OF REVENUE - PREVIOUS GUIDANCE WAS IN THE RANGE OF 27% – 29%.UCB SA - THESE CHANGES ARE DRIVEN BY BETTER THAN EXPECTED NET SALES, DUE TO STRONG DEMAND FOR CIMZIA® AND VIMPAT® IN THE FOURTH QUARTER 2019. TO OPTIMIZE THE GROWTH OPPORTUNITY ADDITIONAL MARKETING ACTIVITIES WERE FUNDED.  Full Article

UCB To Build New Biotech Manufacturing Plant In Belgium
Wednesday, 18 Dec 2019 

Dec 18 (Reuters) - Ucb SA ::UCB TO BUILD NEW BIOTECH MANUFACTURING PLANT IN BELGIUM.CONSTRUCTION IS DUE TO START IN Q1 OF 2020.NEW FACILITY, REPRESENTING AN INVESTMENT OF MORE THAN 300 MILLION EUROS OVER COMING YEARS, IS EXPECTED TO BE OPERATIONAL IN 2024.UCB IS EXPECTING TO CREATE MORE THAN 150 NEW, HIGH SKILLED JOBS ONCE PLANT BECOMES FULLY OPERATIONAL.  Full Article

UCB Presents Final Results from Phase II Study of Rozanolixizumab
Tuesday, 10 Dec 2019 

Dec 9 (Reuters) - Ucb SA ::UCB PRESENTS FINAL RESULTS FROM PHASE II STUDY OF ROZANOLIXIZUMAB IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP).PHASE II DATA DEMONSTRATE THAT ROZANOLIXIZUMAB WAS WELL TOLERATED BY PATIENTS WITH PRIMARY ITP ACROSS ALL DOSE GROUPS.SAFETY, TOLERABILITY AND EFFICACY DATA SUPPORT PHASE III DEVELOPMENT OF ROZANOLIXIZUMAB FOR PRIMARY ITP.  Full Article

BRIEF-UCB And Ferring Pharmaceuticals Announce Co-Promotion Of Cimzia®

* UCB AND FERRING PHARMACEUTICALS ANNOUNCE CO-PROMOTION OF CIMZIA® (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE CROHN'S DISEASE